Enhancement of radiosensitivity by 5-Aza-CdR through activation of G2/M checkpoint response and apoptosis in osteosarcoma cells

Tumor Biology

Volumn 35, Issue 5, 2014, Pages 4831-4839

  Li, Yi ^a,b   Geng, PeiLiang ^a   Jiang, Weihao ^c   Wang, Yunlai ^a   Yao, Jie ^d   Lin, Xu ^b   Liu, Jun ^b   Huang, Lichun ^b   Su, Bin ^b   Chen, Hong ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b KUNMING GENERAL HOSPITAL   (China)

^c Beijing 307 Hospital   (China)

^d Department of Oncology PLA No 161 Center Hospital   (China)

Author keywords

5 Aza 2 CdR; Apoptosis; G2 M arrest; Osteosarcoma; Radiosensitization

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; MESSENGER RNA; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE; CHECKPOINT KINASE 2; CHEK2 PROTEIN, HUMAN; DAPK1 PROTEIN, HUMAN; DEATH ASSOCIATED PROTEIN KINASE; DRUG DERIVATIVE; EXORIBONUCLEASE; PROTEIN 14 3 3; SFN PROTEIN, HUMAN; TUMOR MARKER;

APOPTOSIS; ARTICLE; CELL ACTIVATION; CHK2 GENE; CONTROLLED STUDY; DAPK1 GENE; DEMETHYLATION; DRUG EFFECT; DRUG MECHANISM; G2 PHASE CELL CYCLE CHECKPOINT; GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IRRADIATION; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROMOTER REGION; RADIOSENSITIVITY; SAOS 2 CELL LINE; THERAPY EFFECT; U2OS CELL LINE; UPREGULATION; BONE TUMOR; CELL CYCLE G2 PHASE; CELL DIVISION; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; RADIATION DOSE; TUMOR CELL LINE;

14-3-3 PROTEINS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; AZACITIDINE; BONE NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; CHECKPOINT KINASE 2; DEATH-ASSOCIATED PROTEIN KINASES; EXORIBONUCLEASES; G2 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OSTEOSARCOMA; RADIATION TOLERANCE; TUMOR MARKERS, BIOLOGICAL;

EID: 84902990820     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1634-5     Document Type: Article

References (36)

1. Dai X et al. Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing's sarcoma. Med Sci Monit. 2011;17(8):RA177-90.
2. Ta HT et al. Osteosarcoma treatment: state of the art. Cancer Metastasis Rev. 2009;28(1-2):247-63.
3. Juergens RA, Rudin CM. Aberrant epigenetic regulation. Am Soc Clin Oncol Educ Book. 2013;2013:295-300.
4. Virani S et al. Cancer epigenetics: a brief review. ILAR J. 2012;53(3-4):359-69.
5. Mani S, Herceg Z. DNA demethylating agents and epigenetic therapy of cancer. Adv Genet. 2010;70:327-40.
6. Fathi AT, Abdel-Wahab O. Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy. Adv Hematol. 2012;2012:469592.
7. Shih AH et al. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer. 2012;12(9):599-612.
8. Karahoca M, Momparler RL. Pharmacokinetic and pharmacodynamic analysis of 5-aza-2′-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. Clin Epigenetics. 2013;5(1):3.
9. Cho HJ et al. The combination effect of sodium butyrate and 5-Aza-2′-deoxycytidine on radiosensitivity in RKO colorectal cancer and MCF-7 breast cancer cell lines. World J Surg Oncol. 2009;7:49.
10. Brieger J et al. Pharmacological genome demethylation increases radiosensitivity of head and neck squamous carcinoma cells. Int J Mol Med. 2012;29(3):505-9.
11. Dunne AL et al. Relationship between clonogenic radiosensitivity, radiation-induced apoptosis and DNA damage/repair in human colon cancer cells. Br J Cancer. 2003;89(12):2277-83. (Pubitemid 38168011)
12. Li Y, Meng G, Guo QN. Changes in genomic imprinting and gene expression associated with transformation in a model of human osteosarcoma. Exp Mol Pathol. 2008;84(3):234-9.
13. Lal G et al. Regulation of 14-3-3sigma expression in human thyroid carcinoma is epigenetically regulated by aberrant cytosine methylation. Cancer Lett. 2008;267(1):165-74.
14. Ahmad ST et al. Methylation of the APAF-1 and DAPK-1 promoter region correlates with progression of renal cell carcinoma in North Indian population. Tumour Biol. 2012;33(2):395-402.
15. Wang H et al. Chk2 down-regulation by promoter hypermethylation in human bulk gliomas. Life Sci. 2010;86(5-6):185-91.
16. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150(1):12-27.
17. Qiu H et al. DNA methyltransferase inhibitor 5-aza-CdR enhances the radiosensitivity of gastric cancer cells. Cancer Sci. 2009;100(1):181-8.
18. Dote H et al. Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine. Clin Cancer Res. 2005;11(12):4571-9. (Pubitemid 40825648)
19. De Schutter H et al. A systematic assessment of radiation dose enhancement by 5-Aza-2′-deoxycytidine and histone deacetylase inhibitors in head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2009;73(3):904-12.
20. Kim HJ et al. DNMT (DNA methyltransferase) inhibitors radiosensitize human cancer cells by suppressing DNA repair activity. Radiat Oncol. 2012;7:39.
21. Trougakos IP et al. Genome-wide transcriptome profile of the human osteosarcoma Sa OS and U-2 OS cell lines. Cancer Genet Cytogenet. 2010;196(2):109-18.
22. Gravina GL et al. Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation. Mol Cancer. 2010;9:305.
23. Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer. 2011;11(4):239-53.
24. Sinclair WK. Cyclic x-ray responses in mammalian cells in vitro. Radiat Res. 1968;33(3):620-43.
25. Shin DY et al. Decitabine, a DNA methyltransferases inhibitor, induces cell cycle arrest at G2/M phase through p53-independent pathway in human cancer cells. Biomed Pharmacother. 2013;67(4):305-11.
26. Jabbour E et al. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer. 2008;112(11):2341-51.
27. Mhawech P et al. Downregulation of 14-3-3sigma in ovary, prostate and endometrial carcinomas is associated with CpG island methylation. Mod Pathol. 2005;18(3):340-8. (Pubitemid 40395351)
28. Schultz J et al. 14-3-3sigma gene silencing during melanoma progression and its role in cell cycle control and cellular senescence. Mol Cancer. 2009;8:53.
29. Hermeking H, Benzinger A. 14-3-3 proteins in cell cycle regulation. Semin Cancer Biol. 2006;16(3):183-92. (Pubitemid 43810261)
30. Steiner M et al. 14-3-3sigma mediates G2-M arrest produced by 5-aza-2′-deoxycytidine and possesses a tumor suppressor role in endometrial carcinoma cells. Gynecol Oncol. 2012;127(1):231-40.
31. Schildhaus HU et al. Promoter hypermethylation of p16INK4a, E-cadherin, O6-MGMT, DAPK and FHIT in adenocarcinomas of the esophagus, esophagogastric junction and proximal stomach. Int J Oncol. 2005;26(6):1493-500.
32. Leung RC et al. Promoter methylation of death-associated protein kinase and its role in irradiation response in cervical cancer. Oncol Rep. 2008;19(5):1339-45.
33. Bar-Sela G, Jacobs KM, Gius D. Histone deacetylase inhibitor and demethylating agent chromatin compaction and the radiation response by cancer cells. Cancer J. 2007;13(1):65-9.
34. Ljungman M. The influence of chromatin structure on the frequency of radiation-induced DNA strand breaks: a study using nuclear and nucleoid monolayers. Radiat Res. 1991;126(1):58-64.
35. Rogakou EP et al. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998;273(10):5858-68. (Pubitemid 28124064)
36. Tashiro S, Sun J. Ionizing radiation-induced DNAdamage and repair. Nihon Rinsho. 2012;70(3):383-7.